Sippican Capital Advisors Purchases 7,135 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Sippican Capital Advisors grew its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 30.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,313 shares of the company’s stock after acquiring an additional 7,135 shares during the period. Sippican Capital Advisors’ holdings in Apellis Pharmaceuticals were worth $874,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Apellis Pharmaceuticals in the 1st quarter valued at $89,000. nVerses Capital LLC increased its holdings in Apellis Pharmaceuticals by 300.0% in the second quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after purchasing an additional 2,100 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after buying an additional 781 shares during the period. CWM LLC lifted its stake in shares of Apellis Pharmaceuticals by 299.9% in the second quarter. CWM LLC now owns 4,151 shares of the company’s stock worth $159,000 after acquiring an additional 3,113 shares during the period. Finally, Russell Investments Group Ltd. lifted its stake in shares of Apellis Pharmaceuticals by 1,300.8% in the first quarter. Russell Investments Group Ltd. now owns 3,586 shares of the company’s stock worth $211,000 after acquiring an additional 3,330 shares during the period. Institutional investors own 96.29% of the company’s stock.

Insider Transactions at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $36.23, for a total value of $1,340,510.00. Following the sale, the director now directly owns 100,000 shares of the company’s stock, valued at $3,623,000. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 6.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Wells Fargo & Company lowered their price target on shares of Apellis Pharmaceuticals from $47.00 to $43.00 and set an “equal weight” rating for the company in a report on Tuesday, September 24th. Robert W. Baird decreased their price target on Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating for the company in a report on Monday, September 23rd. UBS Group decreased their target price on Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Wedbush boosted their price target on Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Finally, Mizuho reduced their price objective on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research report on Thursday, October 24th. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $65.41.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ APLS traded down $0.21 during trading on Thursday, reaching $27.50. 14,619 shares of the stock traded hands, compared to its average volume of 1,678,776. The company has a 50-day moving average of $32.76 and a 200-day moving average of $38.01. Apellis Pharmaceuticals, Inc. has a 52-week low of $26.28 and a 52-week high of $73.80. The stock has a market capitalization of $3.34 billion, a P/E ratio of -8.01 and a beta of 0.87. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.03. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The company had revenue of $199.70 million during the quarter, compared to analysts’ expectations of $190.89 million. During the same period in the previous year, the business earned ($1.02) earnings per share. The firm’s quarterly revenue was up 110.2% compared to the same quarter last year. Analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.37 EPS for the current fiscal year.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).